- Report
- January 2024
- 200 Pages
Global
From €4796EUR$5,000USD£4,120GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1919EUR$2,000USD£1,648GBP
- Report
- October 2023
- 188 Pages
Global
From €4701EUR$4,900USD£4,038GBP
- Report
- January 2023
- 125 Pages
Global
From €2389EUR$2,490USD£2,052GBP
- Report
- January 2022
- 200 Pages
Global
From €7195EUR$7,500USD£6,181GBP
- Report
- January 2022
- 200 Pages
Global
From €7195EUR$7,500USD£6,181GBP
- Report
- January 2022
- 60 Pages
Global
From €3789EUR$3,950USD£3,255GBP
- Report
- January 2023
- 167 Pages
Global
From €3453EUR$3,600USD£2,967GBP
- Report
- January 2023
- 79 Pages
Middle East, Africa
From €1439EUR$1,500USD£1,236GBP
- Report
- January 2023
- 80 Pages
Asia Pacific
From €1439EUR$1,500USD£1,236GBP
- Report
- January 2023
- 79 Pages
Europe
From €1439EUR$1,500USD£1,236GBP
- Report
- January 2023
- 73 Pages
North America
From €1439EUR$1,500USD£1,236GBP
- Report
- June 2023
- 123 Pages
Global
From €3500EUR$3,908USD£3,112GBP
- Report
- May 2023
- 81 Pages
Global
From €3500EUR$3,908USD£3,112GBP
- Report
- May 2022
- 43 Pages
Global
From €1919EUR$2,000USD£1,648GBP
- Report
- December 2022
- 210 Pages
Global
From €3540EUR$3,690USD£3,041GBP
- Report
- May 2023
- 160 Pages
Global
From €5755EUR$5,999USD£4,944GBP
The Emphysema Drug market is a subset of the larger Respiratory Drugs market. It is composed of drugs used to treat emphysema, a chronic lung disease that causes shortness of breath, coughing, and wheezing. These drugs are typically inhaled corticosteroids, bronchodilators, and phosphodiesterase-4 inhibitors. They are used to reduce inflammation, open airways, and improve breathing.
The Emphysema Drug market is highly competitive, with many companies offering similar products. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Novartis, Merck, and Boehringer Ingelheim. Other companies, such as Sunovion, Teva Pharmaceuticals, and Mylan, also offer products in this market. Show Less Read more
